{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:03:52Z","timestamp":1777874632140,"version":"3.51.4"},"reference-count":4,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atenci\u00f3n Primaria"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.aprim.2026.103478","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:40:42Z","timestamp":1773056442000},"page":"103478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["El t\u00edtulo correcto es \u00abReacciones adversas de los an\u00e1logos del GLP1, cuando se utilizan para tratar la obesidad en pacientes que no son diab\u00e9ticos\u00bb"],"prefix":"10.1016","volume":"58","author":[{"given":"Maria Estrella","family":"Barcelo Colomer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-1463","authenticated-orcid":false,"given":"Eladio","family":"Fern\u00e1ndez Liz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.aprim.2026.103478_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.aprim.2025.103411","article-title":"Efectos secundarios y farmacovigilancia de los agonistas GLP1","volume":"58","author":"Maria Tablado","year":"2026","journal-title":"Aten Primaria."},{"key":"10.1016\/j.aprim.2026.103478_bib0030","unstructured":"CIMA. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Disponible en: https:\/\/cima.aemps.es\/cima\/publico\/home.html"},{"key":"10.1016\/j.aprim.2026.103478_bib0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.58347\/tml.2023.1692c","article-title":"Tirzepatide (Zepbound) for chronic weight management","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther."},{"key":"10.1016\/j.aprim.2026.103478_bib0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists for weight loss among adults without diabetes: A systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med."}],"container-title":["Atenci\u00f3n Primaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656726000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0212656726000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:06:57Z","timestamp":1777579617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0212656726000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":4,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0212656726000363"],"URL":"https:\/\/doi.org\/10.1016\/j.aprim.2026.103478","relation":{},"ISSN":["0212-6567"],"issn-type":[{"value":"0212-6567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"El t\u00edtulo correcto es \u00abReacciones adversas de los an\u00e1logos del GLP1, cuando se utilizan para tratar la obesidad en pacientes que no son diab\u00e9ticos\u00bb","name":"articletitle","label":"Article Title"},{"value":"Atenci\u00f3n Primaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aprim.2026.103478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"103478"}}